AlphAIalphai — Financial news for AI agents
yahoo.comJUL 217 min read$ANGO

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

Original reporting
yahoo.com
Published Jul 21, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$ANGOBullishMed
01

Why it matters

Traders can update models based on the reported Q4 revenue and segment mix, and incorporate the stated IDE approvals and active pivotal trial timelines into catalyst-driven expectations for FY2027.

02

Market read

The transcript provides actionable quarterly financial datapoints and catalyst updates (IDE approvals, pivotal trial activity, reimbursement/CPT code effectiveness) that can influence near-term positioning.

03

What to watch

Tariff absorption is cited as a headwind; also, the call references divested/discontinued product lines and pro forma metrics, which can complicate apples-to-apples comparisons.

Relevance 7/10Novelty 6/10Timing: after-hours earnings call transcript, ahead of FY2027 positioning

Background

AngioDynamics held its fiscal 2026 fourth quarter and full-year earnings call, emphasizing Med Tech growth, profitability, and upcoming clinical/regulatory catalysts.

Company-level read

Ticker impact

$ANGOBullishMedium confidence
Context

AngioDynamics reports fiscal 2026 Q4 revenue of $86.6M (+8%) and details Med Tech platform mix, catalysts, and leadership transition into FY2027.

Expected impact

Moderate positive bias for the next few sessions as traders digest Q4 numbers and the stated FY2027 outlook/catalysts, with volatility around any guidance specifics not shown in the excerpt.

Evidence & confidence

The article includes concrete Q4 and segment revenue figures plus new catalyst framing (IDE approvals and active pivotal trial). However, the excerpt cuts off before any explicit FY2027 guidance numbers, limiting conviction on magnitude.

Market effects

Sector

Reinforces investor appetite for interventional and cardiovascular med-tech platforms with clinical-data and reimbursement/CPT-code catalysts.

Regional

No clear regional-specific impact beyond U.S. reimbursement and Medicare coverage framework mentioned.

Global

Mentions international adoption following CE mark approval, supporting cross-border demand expectations.

Counterpoint

What could challenge this read

Mechanical Thrombectomy shows mixed performance (AngioVac down YoY while AlphaVac up), and the excerpt does not confirm whether FY2027 guidance meaningfully offsets that variability.

Key entities

  • company
    AngioDynamics

    Med-tech company reporting fiscal 2026 Q4 and full-year results and outlining FY2027 catalysts and CEO transition.

Read at source← All news

Related articles

AUG 8
$GRNDMedAI 8/10

Grindr CEO makes stunning AI reveal that changes the dating game

Grindr CEO George Arison said the dating app is shifting to an AI-native approach, using AI coding tools and expecting AI token costs of about $6 million this year. In Q2, Grindr reported revenue of $138 million, up 33% year over year, beating an estimated $132 million, with paying users up 16% to 1.4 million. Full-year 2026 guidance was raised to about $540 million revenue and $232 million adjusted EBITDA.

yahoo.com6 min
AUG 8
$MATVMed

Mativ Q2 Earnings Call Highlights

Mativ (NYSE:MATV) reported Q2 adjusted EBITDA of $50 million, up more than 18%, and segment margin up 210 bps to 15.3% as pricing offset inflation. Healthcare operations at its Knoxville facility normalized after an outage. Net debt fell to $908 million and net leverage improved to 3.8x. A Menasha, Wisconsin tornado is expected to cut Q3 sales by $20M to $25M.

yahoo.com6 min
AUG 8
$MAINMed

Main Street Capital Q2 Earnings Call Highlights

Main Street Capital (NYSE:MAIN) reported Q2 results on an earnings call. Total investment income was $149.6M (+3.9% YoY, +6.8% QoQ). DNII before taxes was $1.08/share; CFO expects at least $0.97/share in Q3. The board declared a $0.30 supplemental dividend and regular monthly dividends of $0.265/share. MAIN invested about $100M in lower middle market deals and $239M in private loans.

yahoo.com6 min
AUG 8
$LTMMedAI 8/10

LATAM Airlines Group Q2 Earnings Call Highlights

LATAM Airlines Group reported Q2 net income of $125 million and adjusted operating cash flow of $476 million, with nearly $150 million positive cash change before dividends. The company said premium revenue was 29% of passenger revenue and LATAM Pass generated over 67% of passenger revenue. It reinstated 2026 guidance: revenue $17.3B to $17.7B and adjusted EBITDA $4.1B to $4.4B, plus 9% to 10% capacity growth.

yahoo.com6 min
AUG 8
$MAGNMed

Magnera Q3 Earnings Call Highlights

Magnera (NYSE:MAGN) reported Q3 updates on infrastructure and filtration-related sales, with Americas revenue essentially flat year over year. Adjusted EBITDA rose 16% to $71 million in the Americas. The company reaffirmed full-year free cash flow of about $90M to $110M, but expects full-year adjusted EBITDA toward the low end of its prior range, citing inflation and macro uncertainty.

yahoo.com6 min